Pioneering mRNA CEO Stéphane Bancel bags an eye-popping $58M compensation deal in wake of record IPO
We have a winner for the 2018 compensation sweepstakes.
An SEC filing last week revealed that Stéphane Bancel, who made history bringing his biotech unicorn Moderna to Nasdaq in a historic $604 million IPO and a market valuation of $7.5 billion, grabbed a $58 million compensation package for 2018 — with a chunk of stock options providing the bulk of the upside.
Basic subscription required
Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.